Click here to get full coverage on MaxCyte (NASDAQ: MXCT) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan

MaxCyte (NASDAQ: MXCT) faces Nasdaq $1 bid-price deficiency and delisting risk  Stock Titan

MaxCyte (NASDAQ: MXCT) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan

Click here to get full coverage on MaxCyte (MXCT) launches ExPERT DTx platform to accelerate high-throughput drug discovery - MSN

MaxCyte (MXCT) launches ExPERT DTx platform to accelerate high-throughput drug discovery  MSN

MaxCyte (MXCT) launches ExPERT DTx platform to accelerate high-throughput drug discovery - MSN

Click here to get full coverage on MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard  TradingView

MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Click here to get full coverage on Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT - MarketBeat

Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT  MarketBeat

Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT - MarketBeat

Click here to get full coverage on MaxCyte (MXCT) CFO covers RSU tax withholding through automatic share sale - Stock Titan

MaxCyte (MXCT) CFO covers RSU tax withholding through automatic share sale  Stock Titan

MaxCyte (MXCT) CFO covers RSU tax withholding through automatic share sale - Stock Titan

Click here to get full coverage on MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price - TipRanks

MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price  TipRanks

MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price - TipRanks

Click here to get full coverage on MaxCyte (MXCT) Projected to Post Earnings on Tuesday - MarketBeat

MaxCyte (MXCT) Projected to Post Earnings on Tuesday  MarketBeat

MaxCyte (MXCT) Projected to Post Earnings on Tuesday - MarketBeat

Click here to get full coverage on MaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - Quiver Quantitative

MaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026  Quiver Quantitative

MaxCyte, Inc. to Release Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - Quiver Quantitative

Click here to get full coverage on MXCT Technical Analysis & Price Forecast - Intellectia AI

MXCT Technical Analysis & Price Forecast  Intellectia AI

MXCT Technical Analysis & Price Forecast - Intellectia AI

Click here to get full coverage on MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio  Yahoo Finance

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance

Click here to get full coverage on 34% Workforce Reduction: MaxCyte's $13.6M Cost-Cutting Plan Aims to Accelerate Path to Profitability - Stock Titan

34% Workforce Reduction: MaxCyte's $13.6M Cost-Cutting Plan Aims to Accelerate Path to Profitability  Stock Titan

34% Workforce Reduction: MaxCyte's $13.6M Cost-Cutting Plan Aims to Accelerate Path to Profitability - Stock Titan

Click here to get full coverage on MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen - MarketBeat

MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen  MarketBeat

MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen - MarketBeat

Click here to get full coverage on MaxCyte, Inc. (MXCT): A Bull Case Theory - Yahoo Finance

MaxCyte, Inc. (MXCT): A Bull Case Theory  Yahoo Finance

MaxCyte, Inc. (MXCT): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Cell-engineering firm MaxCyte ends 2025 with $155M in cash - Stock Titan

Cell-engineering firm MaxCyte ends 2025 with $155M in cash  Stock Titan

Cell-engineering firm MaxCyte ends 2025 with $155M in cash - Stock Titan

Click here to get full coverage on MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts - MarketBeat

MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts  MarketBeat

MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts - MarketBeat

Click here to get full coverage on New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan

New MaxCyte lab device runs 96 cell samples in a three-minute cycle  Stock Titan

New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan

Click here to get full coverage on MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - MarketBeat

MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen  MarketBeat

MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Click here to get full coverage on MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET - Stock Titan

MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET  Stock Titan

MaxCyte schedules March 24 call on 2025 results for 4:30 p.m. ET - Stock Titan

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - The Manila Times

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026  The Manila Times

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - The Manila Times

Click here to get full coverage on MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company  Yahoo Finance

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance

Click here to get full coverage on MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery - The Manila Times

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery  The Manila Times

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery - The Manila Times

Click here to get full coverage on MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market (NASDAQ:MXCT) - Seeking Alpha

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market (NASDAQ:MXCT)  Seeking Alpha

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market (NASDAQ:MXCT) - Seeking Alpha

Click here to get full coverage on Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT)  Seeking Alpha

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha

Click here to get full coverage on MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% - Stock Titan

MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8%  Stock Titan

MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% - Stock Titan

Click here to get full coverage on MXCT Stock Price and Chart — NASDAQ:MXCT - TradingView

MXCT Stock Price and Chart — NASDAQ:MXCT  TradingView

MXCT Stock Price and Chart — NASDAQ:MXCT - TradingView

Click here to get full coverage on MXCT Forecast — Price Prediction for 2026. Should I Buy MXCT? - Intellectia AI

MXCT Forecast — Price Prediction for 2026. Should I Buy MXCT?  Intellectia AI

MXCT Forecast — Price Prediction for 2026. Should I Buy MXCT? - Intellectia AI

Click here to get full coverage on What is the current Price Target and Forecast for MaxCyte (MXCT) - Zacks Investment Research

What is the current Price Target and Forecast for MaxCyte (MXCT)  Zacks Investment Research

What is the current Price Target and Forecast for MaxCyte (MXCT) - Zacks Investment Research

Click here to get full coverage on MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results - Stock Titan

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results  Stock Titan

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results - Stock Titan

Click here to get full coverage on MaxCyte Q4 Revenue Grows 16%, Adds Six Strategic Partners Amid Cell Therapy Milestone - Stock Titan

MaxCyte Q4 Revenue Grows 16%, Adds Six Strategic Partners Amid Cell Therapy Milestone  Stock Titan

MaxCyte Q4 Revenue Grows 16%, Adds Six Strategic Partners Amid Cell Therapy Milestone - Stock Titan

Click here to get full coverage on Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)  Business Wire

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire

Click here to get full coverage on All News for MXCT : MaxCyte - Zacks Investment Research

All News for MXCT : MaxCyte  Zacks Investment Research

All News for MXCT : MaxCyte - Zacks Investment Research

Click here to get full coverage on MaxCyte cuts 15% of global workforce, boosts core revenue guidance (NASDAQ:MXCT) - Seeking Alpha

MaxCyte cuts 15% of global workforce, boosts core revenue guidance (NASDAQ:MXCT)  Seeking Alpha

MaxCyte cuts 15% of global workforce, boosts core revenue guidance (NASDAQ:MXCT) - Seeking Alpha

Click here to get full coverage on MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance - Stock Titan

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance  Stock Titan

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance - Stock Titan

Click here to get full coverage on Photo Galleries - Oklahoma State University Athletics

Photo Galleries  Oklahoma State University Athletics

Photo Galleries - Oklahoma State University Athletics

Click here to get full coverage on MXCT Forecast — Price Target — Prediction for 2027 - TradingView

MXCT Forecast — Price Target — Prediction for 2027  TradingView

MXCT Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MarketBeat

MaxCyte: Building the Future of Cell and Gene Therapy Innovation  MarketBeat

MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MarketBeat

Click here to get full coverage on Should I buy MaxCyte (MXCT) - Zacks Investment Research

Should I buy MaxCyte (MXCT)  Zacks Investment Research

Should I buy MaxCyte (MXCT) - Zacks Investment Research

Click here to get full coverage on MaxCyte (MXCT) Earnings Date and Reports 2026 - MarketBeat

MaxCyte (MXCT) Earnings Date and Reports 2026  MarketBeat

MaxCyte (MXCT) Earnings Date and Reports 2026 - MarketBeat

Click here to get full coverage on What date does MaxCyte's (MXCT) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research

What date does MaxCyte's (MXCT) report Earnings - Earnings Calendar & Announcement  Zacks Investment Research

What date does MaxCyte's (MXCT) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research

Click here to get full coverage on MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market - PR Newswire

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market  PR Newswire

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market - PR Newswire

Click here to get full coverage on MaxCyte exits 2020 in rude health with revenues ahead of expectations - Proactive Investors

MaxCyte exits 2020 in rude health with revenues ahead of expectations  Proactive Investors

MaxCyte exits 2020 in rude health with revenues ahead of expectations - Proactive Investors

Click here to get full coverage on Thompson J Stark Phd Net Worth (2026) - GuruFocus

Thompson J Stark Phd Net Worth (2026)  GuruFocus

Thompson J Stark Phd Net Worth (2026) - GuruFocus

Click here to get full coverage on Further reaction to this week's news boosts Wey Education and Rosslyn Data Technologies - Proactive Investors

Further reaction to this week's news boosts Wey Education and Rosslyn Data Technologies  Proactive Investors

Further reaction to this week's news boosts Wey Education and Rosslyn Data Technologies - Proactive Investors

Click here to get full coverage on MaxCyte, Inc. (MXCT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

MaxCyte, Inc. (MXCT) Stock Forecast & Price Prediction 2026–2030  CoinCodex

MXCT

Price Chart

Key Statistics

Technicals

About MXCT

Latest News

MaxCyte (NASDAQ: MXCT) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan

MaxCyte (MXCT) launches ExPERT DTx platform to accelerate high-throughput drug discovery - MSN

MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Advanced Charts

Top Gainers

Top Losers